Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cell counts may reveal hidden cancer risk in triple negative breast cancer

NCT ID NCT04068623

Knowledge-focused Sponsor: Centre Jean Perrin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether certain blood cell counts and tumor-infiltrating lymphocytes can help predict if triple negative breast cancer will come back. Researchers will collect blood samples from 90 women after radiation and at the time of any first recurrence. The goal is to find a simple, inexpensive way to identify patients at higher risk of metastatic recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to help predict which patients are at higher risk of their breast cancer returning.
What could go wrong
This is an observational study, not a treatment trial. It is small (90 people) and only looks at correlations, so it may not lead to a reliable test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Oct 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women diagnosed and treated for non metastatic triple negative breast cancer

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female * Age \> 18 years * Diagnosed with primitive, non-metastatic, histologically proved, triple negative breast cancer * Patient treated with chemotherapy, surgery and radiation therapy * Patient able to understand the French language * Patient affiliated to social security * Obtaining signed written consent Exclusion Criteria: * Male * Unavailable tumoral samples before inclusion * Unavailable blood test results at baseline, before inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Triple negative breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Triple negative breast cancer

Contacts and locations

Locations

  • Centre Jean PERRIN

    Clermont-Ferrand, Please Select, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.